Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
Fan R, Papatheodoridis G, Sun J, Innes H, Toyoda H, Xie Q, Mo S, Sypsa V, Guha IN, Kumada T, Niu J, Dalekos G, Yasuda S, Barnes E, Lian J, Suri V, Idilman R, Barclay ST, Dou X, Berg T, Hayes PC, Flaherty JF, Zhou Y, Zhang Z, Buti M, Hutchinson SJ, Guo Y, Calleja JL, Lin L, Zhao L, Chen Y, Janssen HLA, Zhu C, Shi L, Tang X, Gaggar A, Wei L, Jia J, Irving WL, Johnson PJ, Lampertico P, Hou J. Fan R, et al. Among authors: irving wl. J Hepatol. 2020 Dec;73(6):1368-1378. doi: 10.1016/j.jhep.2020.07.025. Epub 2020 Jul 21. J Hepatol. 2020. PMID: 32707225 Free article.
Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study.
Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D, Murray-Lyon L, Irving WL, Goldin RD, Foster GR; UK Amantadine Study Group. Caronia S, et al. Among authors: irving wl. J Hepatol. 2001 Oct;35(4):512-6. doi: 10.1016/s0168-8278(01)00140-4. J Hepatol. 2001. PMID: 11682036 Clinical Trial.
The natural history of hepatitis C with severe hepatic fibrosis.
Lawson A, Hagan S, Rye K, Taguri N, Ratib S, Zaitoun AM, Neal KR, Ryder SD, Irving WL; Trent HCV Study Group. Lawson A, et al. Among authors: irving wl. J Hepatol. 2007 Jul;47(1):37-45. doi: 10.1016/j.jhep.2007.02.010. Epub 2007 Mar 7. J Hepatol. 2007. PMID: 17400322
'Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.
Bucci C, von Delft A, Christian A, Flemming VM, Harrison A, Halliday J, Collier J, Manganis C, Klenerman P, Irving W, Barnes E. Bucci C, et al. J Gen Virol. 2013 Jun;94(Pt 6):1259-1265. doi: 10.1099/vir.0.051052-0. Epub 2013 Mar 13. J Gen Virol. 2013. PMID: 23486666
IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G. Eslam M, et al. Among authors: irving wl. J Hepatol. 2014 Aug;61(2):235-41. doi: 10.1016/j.jhep.2014.03.039. Epub 2014 Apr 24. J Hepatol. 2014. PMID: 24768758
230 results